Inventor · disambiguated record
Longbin Liu
Also filed as: LIU LONGBIN
54 granted patents·13 pending applications·718 citations·filing 1999–2025
98Inventor score
Top patents by PatentIndex Score
67 records- 0198US11905281B2KRAS G12C inhibitors and methods of using the sameAMGEN INC·Filed 2020·Granted Feb 20, 2024·13 cites·16 claims
- 0298US11766436B2KRAS G12C inhibitors and methods of using the sameAMGEN INC·Filed 2021·Granted Sep 26, 2023·11 cites·19 claims
- 0398US11090304B2KRAS G12C inhibitors and methods of using the sameAMGEN INC·Filed 2019·Granted Aug 17, 2021·33 cites·3 claims
- 0498US10519146B2KRAS G12C inhibitors and methods of using the sameAMGEN INC·Filed 2018·Granted Dec 31, 2019·81 cites·33 claims
- 0596US12083121B2Substituted piperazines as KRAS G12C inhibitorsAMGEN INC·Filed 2022·Granted Sep 10, 2024·7 cites·5 claims
- 0696US11285156B2Substituted piperazines as KRAS G12C inhibitorsAMGEN INC·Filed 2019·Granted Mar 29, 2022·16 cites·4 claims
- 0796US8067548B2Fusion proteins having mutated immunoglobulin hinge regionWANG HAITAO·Filed 2008·Granted Nov 29, 2011·36 cites·11 claims
- 0896US7625564B2Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivoNOVAGEN HOLDING CORP·Filed 2006·Granted Dec 1, 2009·41 cites·34 claims
- 0995US7652009B2Substituted heterocycles and methods of useAMGEN INC·Filed 2005·Granted Jan 26, 2010·33 cites·25 claims
- 1094US7820665B2Imidazopyridazine inhibitors of PI3 kinase for cancer treatmentAMGEN INC·Filed 2008·Granted Oct 26, 2010·38 cites·9 claims
- 1194US6187777B1Compounds and methods which modulate feeding behavior and related diseasesAMGEN INC·Filed 1999·Granted Feb 13, 2001·134 cites·20 claims
- 1293US12440491B2KRAS G12C inhibitors and methods of using the sameAMGEN INC·Filed 2023·Granted Oct 14, 2025·1 cites·4 claims
- 1393US9066954B2Fused heterocyclic derivatives and methods of useAMGEN INC·Filed 2013·Granted Jun 30, 2015·22 cites·9 claims
- 1493US6583154B1Compounds and methods which modulate feeding behavior and related diseasesAMGEN INC·Filed 2000·Granted Jun 24, 2003·57 cites·16 claims
- 1592US8524900B2Fused heterocyclic derivatives and methods of useALBRECHT BRIAN K·Filed 2011·Granted Sep 3, 2013·23 cites·8 claims
- 1692US7928140B2Benzothiazole PI3 kinase modulators for cancer treatmentAMGEN INC·Filed 2008·Granted Apr 19, 2011·32 cites·17 claims
- 1791US8431132B2Recombinant human EPO-FC fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivoWANG HAITAO·Filed 2009·Granted Apr 30, 2013·13 cites·23 claims
- 1891US7625555B2Recombinant human interferon-like proteinsNOVAGEN HOLDING CORP·Filed 2007·Granted Dec 1, 2009·13 cites·34 claims
- 1990US11992535B2Compounds and probes for imaging huntingtin proteinCHDI FOUNDATION INC·Filed 2020·Granted May 28, 2024·2 cites·39 claims
- 2089US8088794B2Substituted amide derivatives and methods of useKIM TAE-SEONG·Filed 2010·Granted Jan 3, 2012·14 cites·14 claims
- 2188US2025381187A1Kras g12c inhibitors and methods of using the sameAMGEN INC·Filed 2025·Application pending·0 cites
- 2286US9375487B2Recombinant human EPO-FC fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivoNOVAGEN HOLDING CORP·Filed 2013·Granted Jun 28, 2016·5 cites·10 claims
- 2386US7687522B2Substituted pyridines and pyrimidines and their use in treatment of cancerAMGEN INC·Filed 2007·Granted Mar 30, 2010·8 cites·3 claims
- 2485US11806346B2HTT modulators for treating Huntington's diseaseCHDI FOUNDATION INC·Filed 2021·Granted Nov 7, 2023·1 cites·37 claims
- 2584US11279742B2Recombinant human EPO-FC fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivoNOVAGEN HOLDING CORP·Filed 2018·Granted Mar 22, 2022·1 cites·20 claims
- 2684US8425895B2Recombinant human interferon-like proteinsWANG HAITAO·Filed 2007·Granted Apr 23, 2013·4 cites·48 claims
- 2784US7964375B2Polynucleotides encoding human EPO-FC fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivoNOVAGEN HOLDING CORP·Filed 2009·Granted Jun 21, 2011·4 cites·11 claims
- 2884US2024174660A1Kras g12c inhibitors and methods of using the sameAMGEN INC·Filed 2023·Application pending·0 cites
- 2983US8685983B2Method of treating cancer with substituted amide derivativesKIM TAE-SEONG·Filed 2011·Granted Apr 1, 2014·7 cites·5 claims
- 3083US8017601B2Bis-aryl kinase inhibitors and methodAMGEN INC·Filed 2006·Granted Sep 13, 2011·7 cites·18 claims
- 3183US7915287B2Substituted heterocycles and methods of useAMGEN INC·Filed 2007·Granted Mar 29, 2011·4 cites·21 claims
- 3282US6849639B2Integrin inhibitors and their methods of useAMGEN INC·Filed 2000·Granted Feb 1, 2005·19 cites·8 claims
- 3381US11918662B2Heterocyclic compounds and imaging agents for imaging huntingtin proteinCHDI FOUNDATION INC·Filed 2021·Granted Mar 5, 2024·1 cites·8 claims
- 3481US2023265143A1Recombinant human epo-fc-fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivoNOVAGEN HOLDING CORP·Filed 2022·Application pending·0 cites
- 3580US11028398B2Fusion proteins having mutated immunoglobulin hinge regionWANG HAITAO·Filed 2011·Granted Jun 8, 2021·2 cites·25 claims
- 3680US10117949B2Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivoWANG HAITAO·Filed 2007·Granted Nov 6, 2018·2 cites·27 claims
- 3780US8772480B2Inhibitors of PI3 kinase and/or mTORAMGEN INC·Filed 2012·Granted Jul 8, 2014·5 cites·25 claims
- 3880US7868151B2Recombinant human interferon-like proteinsNOVAGEN HOLDING CORP·Filed 2009·Granted Jan 11, 2011·2 cites·14 claims
- 3979US9234022B2Recombinant human interferon-like proteins and method of treatment using themNOVAGEN HOLDING CORP·Filed 2013·Granted Jan 12, 2016·2 cites·42 claims
- 4078US7867482B2Recombinant human interferon-like proteinsNOVAGEN HOLDING CORP·Filed 2009·Granted Jan 11, 2011·2 cites·30 claims
- 4177US8729074B2Inhibitors of PI3 kinaseBO YUNXIN Y·Filed 2010·Granted May 20, 2014·5 cites·2 claims
- 4274US7504403B2Substituted heterocyclic compounds and methods of useAMGEN INC·Filed 2005·Granted Mar 17, 2009·2 cites·17 claims
- 4374US7049318B2Substituted heterocyclic compounds and methods of useAMGEN INC·Filed 2004·Granted May 23, 2006·9 cites·20 claims
- 4473US2020369741A1Recombinant human interferon-like proteinsNOVAGEN HOLDING CORP·Filed 2019·Application pending·0 cites
- 4570US8415376B2Inhibitors of PI3 kinaseBO YUNXIN Y·Filed 2009·Granted Apr 9, 2013·1 cites·9 claims
- 4670US2020055845A1Kras g12c inhibitors and methods of using the sameAMGEN INC·Filed 2019·Application pending·0 cites
- 4769US12083108B2Compounds for targeting mutant huntingtin protein and uses thereofCHDI FOUNDATION INC·Filed 2022·Granted Sep 10, 2024·0 cites·17 claims
- 4869US10538565B2Method of treating diseases with recombinant human interferon-like proteinsNOVAGEN HOLDING CORP·Filed 2018·Granted Jan 21, 2020·0 cites·14 claims
- 4969US9550762B2Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of useAMGEN INC·Filed 2015·Granted Jan 24, 2017·1 cites·95 claims
- 5068US2022127623A1Fusion proteins having mutated immunoglobulin hinge regionNOVAGEN HOLDING CORP·Filed 2021·Application pending·0 cites
Showing the top 50 of 67 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Longbin Liu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →